BRPI0924041A2 - terapias de combinação para distúrbios neoplásicos - Google Patents

terapias de combinação para distúrbios neoplásicos

Info

Publication number
BRPI0924041A2
BRPI0924041A2 BRPI0924041A BRPI0924041A BRPI0924041A2 BR PI0924041 A2 BRPI0924041 A2 BR PI0924041A2 BR PI0924041 A BRPI0924041 A BR PI0924041A BR PI0924041 A BRPI0924041 A BR PI0924041A BR PI0924041 A2 BRPI0924041 A2 BR PI0924041A2
Authority
BR
Brazil
Prior art keywords
combination therapies
neoplastic disorders
neoplastic
disorders
therapies
Prior art date
Application number
BRPI0924041A
Other languages
English (en)
Inventor
Caroline B Ho
Christopher B Proffitt
Denis Drygin
Joshua R Bliesath
Kenna Anderes
Sean O' Brien
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of BRPI0924041A2 publication Critical patent/BRPI0924041A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0924041A 2009-01-08 2009-06-10 terapias de combinação para distúrbios neoplásicos BRPI0924041A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14328209P 2009-01-08 2009-01-08
PCT/US2009/046948 WO2010080170A1 (en) 2009-01-08 2009-06-10 Combination therapies for neoplastic disorders

Publications (1)

Publication Number Publication Date
BRPI0924041A2 true BRPI0924041A2 (pt) 2016-01-26

Family

ID=40973134

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924041A BRPI0924041A2 (pt) 2009-01-08 2009-06-10 terapias de combinação para distúrbios neoplásicos

Country Status (13)

Country Link
EP (1) EP2381942A1 (pt)
JP (1) JP2012514638A (pt)
KR (1) KR20110116153A (pt)
CN (1) CN102341107A (pt)
AU (1) AU2009336141A1 (pt)
BR (1) BRPI0924041A2 (pt)
CA (1) CA2749261A1 (pt)
IL (1) IL213969A0 (pt)
MX (1) MX2011007384A (pt)
RU (1) RU2011133093A (pt)
SG (1) SG172922A1 (pt)
WO (1) WO2010080170A1 (pt)
ZA (1) ZA201105755B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA3116731A1 (en) * 2018-10-19 2020-04-23 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN114869903A (zh) * 2022-06-14 2022-08-09 苏天生命科技(苏州)有限公司 巴弗洛霉素a1在优化急性淋系白血病化疗组合药物中的应用
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
WO2008127707A1 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling

Also Published As

Publication number Publication date
CA2749261A1 (en) 2010-07-15
IL213969A0 (en) 2011-08-31
CN102341107A (zh) 2012-02-01
EP2381942A1 (en) 2011-11-02
RU2011133093A (ru) 2013-02-20
AU2009336141A1 (en) 2011-08-11
MX2011007384A (es) 2011-12-14
ZA201105755B (en) 2012-04-25
SG172922A1 (en) 2011-08-29
KR20110116153A (ko) 2011-10-25
WO2010080170A1 (en) 2010-07-15
JP2012514638A (ja) 2012-06-28

Similar Documents

Publication Publication Date Title
PT2515855E (pt) Terapêutica de combinação para dpoc
DK3421603T3 (da) Genterapi for neurodegenerative forstyrrelser
BR112012011730A2 (pt) tratamentos para distúrbios gastrointestinais
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0909221A2 (pt) Desordens neurodegenerativas
ES1073507Y (es) Dispositivo de fijacion para tarimas
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
BRPI1009191A2 (pt) dispositivo para administração intranasal
CO6852034A2 (es) Conjunto de placas de realces para tolvas mejorado
BRPI0924041A2 (pt) terapias de combinação para distúrbios neoplásicos
BRPI0909659A2 (pt) tratamento para distúrbios relacionados oculares
ES1074376Y (es) Trituradora mejorada para restos de poda
ES1074173Y (es) Pieza para solados
ES1075221Y (es) Vallado cortavientos para parques termosolares
ES1065835Y (es) Caperuza para cetreria
ES1070148Y (es) Macolla para barrotes mejorada
ES1072303Y (es) Racor de conexion para conducciones
ES1067107Y (es) Entresuela para calzado
ES1071124Y (es) Parapente para aeromodelismo
ES1070663Y (es) Cenicero exclusivo para c0lillas
ES1071628Y (es) Mecanismo de descarga para cisternas
ES1073423Y (es) Mastil para banderola
ES1075130Y (es) Ortesis terapeutica para miembro inferior
ES1069850Y (es) Butaca para vehiculos
ES1065263Y (es) Captafaros para bionda

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.